First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial

作者：Aiping Zhou, Pengfei Shen, Juan Li, Wang Qu, Zengjun Wang, Xiubao Ren, Yuan Li, Shusuan Jiang, Gang Li, Yu Zeng, Weijun Qin, Jin Wu, Peng Chen, Fangjian Zhou, Hongqian Guo, Zhigang Ji, Yongquan Wang, Zhisong He, Jitao Wu, Benkang Shi, Lian Liu, Xudong Yao, Lulin Ma, Ziling Liu, Xin Gou, Bin Fu, Shao-Gang Wang, Kui Jiang, Tie Chong, Xinhua Tu, Xu Zhang, De‐Xin Yu, Mulati Rexiati, Xueyi Xue, Fei Jing, Jianghou Wan, Liqun Jia, Yi He, Tongjian Cui, Anqi Yang, Jun Guo, Xinan Sheng · 发表于：The Lancet Oncology · 年份：2025 · DOI：10.1016/s1470-2045(25)00343-2 · 被引用次数：13 · 研究领域：Renal cell carcinoma treatment、Cancer Immunotherapy and Biomarkers、Lung Cancer Research Studies